Real-World Study Shows Comparable Effectiveness of Four Monoclonal Antibodies in Severe Asthma Treatment
核心洞察
A retrospective study of 154 patients with uncontrolled severe asthma (搜索) demonstrated significant improvements in asthma control, lung function, and reduced exacerbations across four monoclonal antibodies (搜索) after 12 months of treatment.
All four biologics (benralizumab, mepolizumab, omalizumab, and reslizumab) showed comparable effectiveness with median ACT scores increasing by six points and FEV₁ improving by 7%.
The study revealed high treatment adherence at 95% and median persistence of 2.0 years, though 42% of patients discontinued therapy primarily due to insufficient clinical response or drug supply issues.
A comprehensive real-world study conducted at Hospital General Universitario Gregorio Marañón in Madrid has demonstrated that four monoclonal antibodies (搜索) targeting type 2 inflammation (搜索) show comparable effectiveness in treating uncontrolled severe asthma (搜索). The retrospective observational study, published in Frontiers in Medicine, analyzed outcomes from 154 patients across 188 treatment episodes over a median follow-up period of 2.2 years.
Significant Clinical Improvements Across All Biologics
The study evaluated benralizumab, mepolizumab, omalizumab, and reslizumab in patients who initiated treatment between January 2015 and December 2022. All four monoclonal antibodies (搜索) were associated with significant improvements in asthma control at 12 months, with median Asthma Control Test (ACT) scores increasing by six points across all treatment groups.
Lung function improvements were consistent, with forced expiratory volume in one second (FEV₁) improving by 7% across all therapies. The study also documented significant reductions in annual exacerbation rates and healthcare utilization across all treatment groups.
Distinct Eosinophil Response Patterns
While all biologics demonstrated clinical efficacy, notable differences emerged in their impact on blood eosinophil (搜索) counts. Benralizumab and reslizumab were associated with the greatest reductions in eosinophil counts, with near-complete depletion observed in patients treated with these agents. Blood eosinophil counts declined across all therapies, reflecting the targeted mechanism of action against type 2 inflammation (搜索).
High Adherence but Notable Discontinuation Rates
The study revealed encouraging adherence patterns, with 95% of patients maintaining high adherence to their prescribed biologic therapy. Median treatment persistence reached 2.0 years (interquartile range 1.4-4.1 years), supporting the feasibility of these treatments in real-world clinical settings.
However, 42% of patients discontinued treatment during the study period. The primary reasons for discontinuation were insufficient clinical response (48.4%) and drug supply issues (42.2%), highlighting ongoing challenges in severe asthma (搜索) management despite the availability of targeted biologics.
Clinical Assessment Parameters
The researchers evaluated multiple clinical, functional, and laboratory outcomes at baseline and after twelve months of treatment. Key assessment parameters included eosinophil (搜索) count, fractional exhaled nitric oxide (FeNO), ACT scores, exacerbation frequency, emergency visits, and hospitalizations. Data were extracted from electronic health records and presented as median values with interquartile ranges.
Implications for Severe Asthma Management
The findings suggest that uncontrolled severe asthma (搜索), which represents a substantial clinical and economic burden particularly in patients with comorbidities and poor response to high-dose inhaled corticosteroids, can be effectively managed with monoclonal antibodies (搜索) targeting type 2 inflammation (搜索). The comparable effectiveness across the four biologics supports flexible treatment selection based on individual patient phenotypes.
The study's authors emphasized that these results underscore the relevance of phenotype-driven therapy selection and highlight the need for long-term monitoring to optimize outcomes in severe asthma (搜索) management. The real-world data provides valuable insights into the practical application of these targeted therapies beyond controlled clinical trial settings.